Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial.
Lancet HaematolOct 1, 2026
Haiyan He, Jingjing Shang, Yafei Wang et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 3 randomized trial evaluated the efficacy of felzartamab combined with lenalidomide-dexamethasone versus lenalidomide-dexamethasone alone in Chinese patients with relapsed or refractory multiple myeloma. The study found that the combination therapy significantly improved median progression-free survival, with 18.9 months for the combination group compared to 10.4 months for the control group (hazard ratio 0.62; p=0.0035).
Key findings
- Median progression-free survival was 18.9 months with felzartamab versus 10.4 months with lenalidomide-dexamethasone.
- The hazard ratio for progression-free survival was 0.62 (95% CI 0.45-0.86; p=0.0035).
- 55% of patients in the felzartamab group experienced grade 3-4 neutropenia compared to 23% in the control group.
- Treatment-related deaths occurred in 6% of the felzartamab group versus 2% in the lenalidomide-dexamethasone group.
Why it matters
The findings suggest that felzartamab combined with lenalidomide-dexamethasone may offer a more effective treatment option for patients with relapsed or refractory multiple myeloma, potentially improving patient outcomes.